Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe